At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $487M
Founded date: 2021
Investors 7
| Date | Name | Website |
| 26.10.2025 | Jeito Capi... | jeito.life |
| 06.03.2022 | Foresite C... | foresiteca... |
| - | OrbiMed | orbimed.co... |
| - | HBM Partne... | hbmpartner... |
| - | Catalio Ca... | cataliocap... |
| - | Balderton ... | balderton.... |
| 09.12.2021 | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 05.12.2023 | Series C | $101M | - |
| 17.10.2022 | Series B | $168M | Logos Capi... |
| 08.12.2021 | Series A | $218M | - |
Mentions in press and media 13
| Date | Title | Description |
| 11.09.2025 | Odyssey Therapeutics Raises $213M in Series D Financing | Odyssey Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company, raised $213M in Series D funding. Backers included Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovati... |
| 10.09.2025 | Odyssey Therapeutics heralds $213M series D to strengthen clinical portfolio | Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D after abandoning plans to go public this summer. All of Odyssey’s existing investors pitched in for th... |
| 05.12.2023 | Odyssey Therapeutics Raises $101M in Series C Financing | Odyssey Therapeutics, a Boston, MA-based biotechnology company developing precision immunomodulators and oncology medicines, raised $101M in Series C funding. The round, which brought the total amount to $487M, was led by Ascenta Capital wi... |
| 13.10.2022 | Odyssey Therapeutics Raises $168M in Series B Financing | Odyssey Therapeutics, a Boston, MA-based biotechnology company, raised $168M in Series B funding. The round was led by General Catalyst, with participation from Fidelity Management & Research Company, T. Rowe Price Associates, GreatPoin... |
| 13.10.2022 | 10 months after first mega round, Glick's Odyssey raises $168M to gear up for entering clinic | The Odyssey Therapeutics story is progressing quickly. Ten months after disclosing a $218 million series A, the Gary Glick-helmed biotech is back with another mega round as it prepares to push candidates into clinic-enabling studies next ye... |
| 13.10.2022 | Odyssey Therapeutics Announces Oversubscribed $168 Million Series B Financing | - |
| 25.04.2022 | London’s BenevolentAI lists on Euronext Amsterdam to boost drug discovery in Europe | London-headquartered clinical-stage AI-enabled drug discovery company, BenevolentAI has begun trading on Euronext Amsterdam. The listing follows the completion of its business combination with Amsterdam-listed Odyssey. Odyssey had bought Be... |
| 08.12.2021 | Odyssey Therapeutics Raises $218M in Series A Financing | Odyssey Therapeutics, a Boston MA-based biotechnology company advancing next generation precision immunomodulators and oncology medicines, raised $218M in Series A funding. The round was led by OrbiMed Advisors and SR One Capital Management... |
| - | Odyssey Therapeutics | “Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases” |
| - | Odyssey Therapeutics | “Odyssey Therapeutics is making epic leaps in inflammation and oncology medicines by innovating with groundbreaking speed.” |
Show more